Clementia Pharmaceuticals (CMTA) Earning Somewhat Favorable News Coverage, Study Shows

Media stories about Clementia Pharmaceuticals (NASDAQ:CMTA) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Clementia Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.4946088610533 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Clementia Pharmaceuticals (NASDAQ:CMTA) opened at $16.00 on Tuesday. Clementia Pharmaceuticals has a 1 year low of $15.05 and a 1 year high of $18.95.

Several analysts have recently weighed in on CMTA shares. BTIG Research started coverage on shares of Clementia Pharmaceuticals in a research note on Thursday, August 31st. They issued a “buy” rating and a $32.00 price target for the company. Morgan Stanley started coverage on shares of Clementia Pharmaceuticals in a research note on Monday, August 28th. They issued an “overweight” rating and a $27.00 price target for the company. Wedbush started coverage on shares of Clementia Pharmaceuticals in a research note on Monday, August 28th. They issued an “outperform” rating and a $26.00 price target for the company. Finally, Leerink Swann started coverage on shares of Clementia Pharmaceuticals in a research note on Monday, August 28th. They issued an “outperform” rating and a $23.00 price target for the company.

COPYRIGHT VIOLATION WARNING: “Clementia Pharmaceuticals (CMTA) Earning Somewhat Favorable News Coverage, Study Shows” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/05/clementia-pharmaceuticals-cmta-earning-somewhat-favorable-news-coverage-study-shows.html.

About Clementia Pharmaceuticals

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.

Insider Buying and Selling by Quarter for Clementia Pharmaceuticals (NASDAQ:CMTA)

What are top analysts saying about Clementia Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Clementia Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit